JY
KRYS icon

Jeff Yass’s Krystal Biotech KRYS Stock Holding History

Jeff Yass’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Sell
56,900
-35,800
-39% -$10.7M ﹤0.01% 2410
2026
Q1 		$23.9M Buy
92,700
+47,500
+105% +$12.6M ﹤0.01% 2001
2025
Q4 		$11.1M Sell
45,200
-68,600
-60% -$14.4M ﹤0.01% 2914
2025
Q3 		$20.1M Sell
113,800
-75,100
-40% -$11.2M ﹤0.01% 2204
2025
Q2 		$26M Buy
188,900
+166,100
+729% +$24.4M ﹤0.01% 1726
2025
Q1 		$4.11M Sell
22,800
-99,700
-81% -$16.8M ﹤0.01% 4024
2024
Q4 		$19.2M Sell
122,500
-190,700
-61% -$33.8M ﹤0.01% 1894
2024
Q3 		$57M Buy
313,200
+199,800
+176% +$38.5M 0.01% 994
2024
Q2 		$20.8M Sell
113,400
-91,100
-45% -$15.3M ﹤0.01% 1679
2024
Q1 		$36.4M Buy
204,500
+74,500
+57% +$10.3M 0.01% 1255
2023
Q4 		$16.1M Buy
130,000
+58,200
+81% +$6.45M ﹤0.01% 2032
2023
Q3 		$8.33M Sell
71,800
-44,800
-38% -$5.47M ﹤0.01% 2787
2023
Q2 		$13.7M Buy
116,600
+74,400
+176% +$7.6M ﹤0.01% 2121
2023
Q1 		$3.38M Buy
42,200
+22,400
+113% +$1.76M ﹤0.01% 4086
2022
Q4 		$1.57M Sell
19,800
-2,200
-10% -$163K ﹤0.01% 5184
2022
Q3 		$1.53M Sell
22,000
-5,000
-19% -$361K ﹤0.01% 5537
2022
Q2 		$1.77M Buy
27,000
+3,500
+15% +$218K ﹤0.01% 5166
2022
Q1 		$1.56M Sell
23,500
-120,700
-84% -$7.53M ﹤0.01% 6031
2021
Q4 		$10.1M Buy
144,200
+6,700
+5% +$390K ﹤0.01% 2705
2021
Q3 		$7.18M Buy
137,500
+126,400
+1,139% +$7.48M ﹤0.01% 3366
2021
Q2 		$755K Sell
11,100
-12,100
-52% -$845K ﹤0.01% 8543
2021
Q1 		$1.79M Buy
23,200
+5,900
+34% +$429K ﹤0.01% 6199
2020
Q4 		$1.04M Buy
+17,300
New +$864K ﹤0.01% 6640

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's KRYS Position: Q2 2026 in Review

Jeff Yass reduced its Krystal Biotech (KRYS) stake by 79% in Q2 2026, selling an estimated $2.13M and leaving 1,899 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #9082.

Jeff Yass first reported a position in KRYS in Q4 2018 and has held it in 29 quarters since. The position peaked at $18.1M in Q1 2024. 421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Jeff Yass held 1,899 shares of Krystal Biotech worth $706K as of Q2 2026.
  • Jeff Yass sold 7,143 Krystal Biotech shares in Q2 2026, an estimated $2.13M.
  • Krystal Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9082 holding.
  • Jeff Yass first reported a position in Krystal Biotech in Q4 2018 and has held it in 29 quarters since.
  • Jeff Yass's Krystal Biotech position peaked at $18.1M in Q1 2024.
  • 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.